Genetics of Insulin and Incretins in Cystic Fibrosis

Launched by CHILDREN'S HOSPITAL OF PHILADELPHIA · May 9, 2013

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how genetics may influence the development of diabetes in people with cystic fibrosis, a condition known as cystic fibrosis-related diabetes (CFRD). Researchers believe that certain genetic factors, similar to those seen in Type 2 Diabetes Mellitus (T2DM), could play a role in how insulin and incretin hormones function in individuals with cystic fibrosis. The study aims to look at different genetic markers in both children and adults with cystic fibrosis to see how these markers relate to their blood sugar levels and hormone responses.

To be eligible for this trial, participants must be over 2 years old and have a confirmed diagnosis of cystic fibrosis. For children under 18, a parent or guardian will need to provide consent. Participants will be involved in tests that measure their insulin and incretin levels, which are important for understanding how their bodies manage glucose. The trial is currently recruiting participants of all genders, and it offers a chance to contribute valuable information that could help improve care for those with cystic fibrosis and related diabetes.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • 1. Subjects age \>2y
• • 2. Diagnosis of Cystic Fibrosis
• • 3. For subjects\< 18 years, parental/guardian permission (informed consent) and if appropriate, child assent
• • Exclusion Criteria 1. Established diagnosis of non-CFRD (cystic fibrosis related diabetes) (e.g T1DM)
• • .